The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MCK | +58.74% | +423.03% | +39.2% | +6,255% |
| S&P | +16.23% | +94.45% | +14.22% | +1,351% |
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $97.83B | 23.4% |
| Gross Profit | $3.11B | 5.1% |
| Gross Margin | 3.18% | -0.6% |
| Market Cap | $91.53B | 20.8% |
| Market Cap / Employee | $2.03M | 0.0% |
| Employees | 45K | -11.8% |
| Net Income | $831.00M | -13.4% |
| EBITDA | $1.23B | 0.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.68B | 16.4% |
| Accounts Receivable | $28.16B | 18.6% |
| Inventory | 25.1K | -2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.39B | 19.0% |
| Short Term Debt | $1.55B | 345.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.14% | -0.2% |
| Return On Invested Capital | 40.32% | 15.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,029.00M | 30.8% |
| Operating Free Cash Flow | -$918.00M | 33.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 25.63 | 26.12 | 26.07 | 29.24 | 11.92% |
| Price to Book | -36.62 | -23.99 | -27.50 | -44.16 | 14.65% |
| Price to Sales | 0.19 | 0.21 | 0.24 | 0.24 | 0.11% |
| Price to Tangible Book Value | -4.62 | -4.93 | -5.81 | -6.43 | 24.60% |
| Price to Free Cash Flow TTM | 14.96 | 45.32 | 16.28 | 16.27 | -31.68% |
| Enterprise Value to EBITDA | 76.00 | 56.25 | 72.91 | 81.43 | 22.44% |
| Free Cash Flow Yield | 6.7% | 2.2% | 6.1% | 6.1% | 46.38% |
| Total Debt | $7.22B | $9.76B | $7.39B | $9.93B | 34.28% |
MCK earnings call for the period ending December 31, 2024.
MCK earnings call for the period ending September 30, 2024.
MCK earnings call for the period ending June 30, 2024.
MCK earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
